About Us

Verve Therapeutics was created with a singular focus: to protect the world from heart disease

Our Mission

Verve is focused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary artery disease, the most common type of heart disease and the leading cause of death worldwide.

Verve brings together two of the biggest breakthroughs in 21st century biomedicine — human genetic analysis and gene editing — to realize a new future, one of longevity and vitality for tens of millions of people worldwide at risk of coronary artery disease.

Verve Team

Verve has been purpose-built for the task ahead, with a founding team of world-leading experts in cardiovascular medicine and patient care, cardiovascular genetics, gene editing delivery technology and safety, drug development, and company-building.

Adelman, Burt, M.D.
Burt Adelman, M.D.
Co-Founder and Chairman of the Board
Alston, Jessica, Ph.D.
Jessica Alston, Ph.D.
Board Observer
Amaonye, Michael
Michael Amaonye
Research Associate
Ashe, Andrew, J.D.
Andrew Ashe, J.D.
President and Chief Operating Officer
Beach, Aaron
Aaron Beach
Principal Scientist, Analytical Chemistry
Bellinger, Andrew, M.D., Ph.D.
Andrew Bellinger, M.D., Ph.D.
Chief Scientific Officer
Biswas, Souvik, Ph.D.
Souvik Biswas, Ph.D.
Senior Scientist
Chadwick, Alexandra, Ph.D.
Alexandra Chadwick, Ph.D.
Associate Director, Preclinical Research and Development
Cheng, Christopher J., Ph.D.
Christopher J. Cheng, Ph.D.
Director, RNA Technology and Manufacturing
Clendaniel, Victoria
Victoria Clendaniel
Research Associate
Colace, Thomas, Ph.D.
Thomas Colace, Ph.D.
Associate Principal Scientist
Cook, Angela
Angela Cook
Chief of Staff
DeNizio, Jamie, Ph.D.
Jamie DeNizio, Ph.D.
Scientist
Dutta, Chaitali, Ph.D.
Chaitali Dutta, Ph.D.
Principal Scientist, Pharmacology and Toxicology
Eisner, Robin
Robin Eisner
Administrative and Operations Manager
Evans, John, MBA
John Evans, MBA
Board Member
Ganey, Jack
Jack Ganey
Associate Scientist
Garcia, Sara, Ph.D.
Sara Garcia, Ph.D.
Senior Scientist, Computational Biology
Joung, J. Keith, M.D., Ph.D.
J. Keith Joung, M.D., Ph.D.
Co-Founder
Kasiewicz, Lisa, Ph.D.
Lisa Kasiewicz, Ph.D.
Scientist
Kathiresan, Sekar, M.D.
Sekar Kathiresan, M.D.
Co-Founder, Chief Executive Officer and Board Member
Malyala, Padma
Padma Malyala
Executive Director, Formulation and Characterization
Martinick, Katie
Katie Martinick
Process Development Engineer
Millman, Robert, J.D.
Robert Millman, J.D.
Intellectual Property and Business Advisor
Mizoguchi, Taiji, Ph.D.
Taiji Mizoguchi, Ph.D.
Scientist
Musunuru, Kiran, M.D., Ph.D., MPH
Kiran Musunuru, M.D., Ph.D., MPH
Co-Founder and Senior Scientific Advisor
Nasrullah, Yusuf
Yusuf Nasrullah
Scientist
Neafus, David, CPA
David Neafus, CPA
Interim Chief Financial Officer
Nikolic, Boris, M.D.
Boris Nikolic, M.D.
Board Observer
Nneji, Joseph
Joseph Nneji
Senior Research Associate
Philippakis, Anthony, M.D., Ph.D.
Anthony Philippakis, M.D., Ph.D.
Co-Founder and Board Member
Rajeev, Kallanthottathil G., Ph.D.
Kallanthottathil G. Rajeev, Ph.D.
Vice President, CMC
Reiss, Caroline, Ph.D.
Caroline Reiss, Ph.D.
Scientist, RNA Technology and Manufacturing
Rohde, Ellen, Ph.D.
Ellen Rohde, Ph.D.
Vice President, Pharmacology and Toxicology
Rozen, Issi, MBA
Issi Rozen, MBA
Co-Founder and Strategic Advisor
Rozen, Michele, MBA
Michele Rozen, MBA
Vice President, Communications
Stolz, Leslie, Ph.D.
Leslie Stolz, Ph.D.
Vice President, Regulatory Affairs
Ticho, Barry, M.D., Ph.D.
Barry Ticho, M.D., Ph.D.
Co-Founder
Wang, Kui, Ph.D.
Kui Wang, Ph.D.
Senior Scientist
Yeshwant, Krishna, M.D., MBA
Krishna Yeshwant, M.D., MBA
Board Member

Scientific Advisory Board

Eugene Braunwald, M.D.
Eugene Braunwald, M.D.
Andrew Geall, Ph.D.
Andrew Geall, Ph.D.
Penny M. Heaton, M.D.
Penny M. Heaton, M.D.
Daniel J. Rader, M.D.
Daniel J. Rader, M.D.

Collaborations and Licensing

Verve has established foundational collaborations with industry leaders in gene editing and delivery technologies, including Beam Therapeutics and Verily. The company also has in-licensed technology from the Broad Institute and Harvard University.

Investors

Verve is supported by a top-tier syndicate of investors who share our vision for tackling the world’s most urgent health challenge.